Total Men's Primary Care - Kyle
5401 Farm to Market 1626 · Kyle, TX 78640
4.9(1,047 Google reviews · 87 in past year)
Accepts insurance
Listing updated Oct 2, 2026
Kyle Medical Spa
Kyle Medical Spa · 1550 Dacy Loop · Kyle, TX 78640
3.0· 1 Google review
Listing updated October 2, 2026
Quick facts
- Address
- 1550 Dacy Loop, Kyle, TX 78640
- Phone
- (512) 551-0846
- Website
- kylemedicalspa.com
- Hours (per its website)
- Mo 08:00:00-16:00:00 · Tu 08:00:00-16:00:00 · We 08:00:00-16:00:00 · Th 08:00:00-16:00:00
- Telehealth
- Not listed
- FDA-approved GLP-1 medications listed
- None listed on its website
- Accepting new patients (per website)
- Yes
- Accepts insurance (per website)
- Yes
- Google rating
- ★3.0 from 1 reviews
- Patient sentiment
- 0% positive, 0% negative (1 reviews analyzed)
- Most common complaint
- None recurring
- Retatrutide
- Not yet available anywhere — investigational, not FDA-approved
- Listing last updated
- October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 3.0
Google rating · 1 reviews
Counts computed by RetaMaps from public Google reviews; most recent review 2024-10-24. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★3.0 across 1 Google reviews. Of the 1 reviews we analyzed, 0 (0%) are positive (4–5★) and 0 (0%) are negative (1–2★).
5★
0
4★
0
3★
1
2★
0
1★
0
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Nearby providers in Kyle
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs